The common goal for all who work in the field of HIV/AIDS research is to control and ultimately end the HIV/AIDS pandemic. In this regard, significant progress has been made in combating HIV/AIDS worldwide. Yet, we must build further on these successes. Inherent in this endeavor is the task of driving down of HIV incidence globally. In order to accomplish this, a combination of non-vaccine and vaccine prevention approaches will be needed. For example, with regard to non-vaccine prevention, recent evidence has highlighted the potential impact of scaling up various iterations of “treatment as prevention” and the selective application of pre-exposure prophylaxis with antiretroviral drugs. Vaccine prevention holds new promise, with efforts to improve upon the modest success of the RV144 trial. On a parallel track to optimizing the RV144 results is the intensive effort to design immunogens that might induce broadly neutralizing antibodies. Furthermore, passive transfer of broadly neutralizing antibodies is being studied as a means to prevent and/or treat HIV infection. While non-vaccine and vaccine-based prevention approaches have the potential to drive HIV incidence toward zero, a significant “implementation gap” remains between the development of interventions and their delivery to people who need them, a gap that must be closed if we are to realize the end of the HIV/AIDS pandemic.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.